期刊
NEUROSCIENCE LETTERS
卷 649, 期 -, 页码 147-155出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2016.11.064
关键词
Posttraumatic stress disorder (PTSD); Glutamate; Glutamine; GABA; NMDA; Neurobiology; Neurotransmission; Novel therapeutics; Treatment; Ketamine; D-Cycloserine
资金
- Department of Veterans Affairs (NCPTSD) [IK2CX000772]
- NIMH [K23MH101498]
- Yale Center for Clinical Investigation [UL1RR024139]
- Janssen Research Foundation
Posttraumatic stress disorder (PTSD) is a chronic and debilitating psychiatric disorder afflicting millions of individuals across the world. While the availability of robust pharmacologic interventions is quite lacking, our understanding of the putative neurobiological underpinnings of PTSD has significantly increased over the past two decades. Accumulating evidence demonstrates aberrant glutamatergic function in mood, anxiety, and trauma-related disorders and dysfunction in glutamate neurotransmission is increasingly considered a cardinal feature of stress-related psychiatric disorders including PTSD. As part of a PTSD Special Issue, this mini-review provides a concise discussion of (1) evidence of glutamatergic abnormalities in PTSD, with emphasis on human subjects data; (2) glutamate-modulating agents as potential alternative pharmacologic treatments for PTSD; and (3) selected gaps in the literature and related future directions. Published by Elsevier Ireland Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据